HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Tyk2 is a therapeutic target for psoriasis-like skin inflammation

Files in This Item:
Tyk2_Matsuda_T_2013.pdf3.17 MBPDFView/Open
Tyk2_Matsuda_T_2013_Supple.pdfSupplementary Data787.44 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Tyk2 is a therapeutic target for psoriasis-like skin inflammation
Authors: Ishizaki, Masayuki Browse this author
Muromoto, Ryuta Browse this author →KAKEN DB
Akimoto, Toshihiko Browse this author
Sekine, Yuichi Browse this author
Kon, Shigeyuki Browse this author →KAKEN DB
Diwan, Manish Browse this author
Maeda, Hiroaki Browse this author
Togi, Sumihito Browse this author
Shimoda, Kazuya Browse this author →KAKEN DB
Oritani, Kenji Browse this author →KAKEN DB
Matsuda, Tadashi Browse this author →KAKEN DB
Keywords: IL-17
Issue Date: 17-Dec-2013
Journal Title: International Immunology
Publisher DOI: 10.1093/intimm/dxt062
PMID: 24345760
Abstract: Tyrosine kinase 2 (Tyk2), a member of the Jak kinase family, mediates signals triggered by various cytokines, which are related to the pathogenesis of psoriasis. In this study, we investigated the role of Tyk2 in IL-23-induced psoriasis-like skin inflammation. Tyk2-/- mice when injected with IL-23 showed significantly reduced ear skin swelling with epidermal hyperplasia and inflammatory cell infiltration compared with wild-type mice. In addition, Tyk2 deficiency reduced production of pro-inflammatory cytokines and psoriasis-relevant anti-microbial peptides. More noteworthy is that Tyk2 directly regulated IL-22-dependent inflammation and epidermal hyperplasia. Taken together with the inhibition of IL-23-induced inflammation by treatment with neutralizing antibodies against IL-17 or IL-22, Tyk2 participates in both IL-23 and IL-22 signal transduction to mediate psoriasis-like skin inflammation. On the basis of these findings, we demonstrated for the first time that a small-molecule Tyk2 inhibitor significantly inhibited IL-23-induced inflammation and cytokine production in the skin. These observations demonstrate the important role of Tyk2 in experimental skin inflammation and indicate the therapeutic potential of Tyk2 inhibition in human psoriasis.
Rights: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in International Immunology following peer review. The definitive publisher-authenticated version "International Immunology 2011 23(9):575-582" is available online at:
Type: article (author version)
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 松田 正

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University